<DOC>
	<DOC>NCT01721096</DOC>
	<brief_summary>The objectives of the PMS are to observe the frequency, type, and degree of device deficiency to assure the safety of the new medical device (XIENCE PRIME) as well as to collect information on evaluation of the efficacy and safety for reevaluation.</brief_summary>
	<brief_title>XIENCE PRIME Japan Post-Marketing Surveillance (PMS)</brief_title>
	<detailed_description>The primary objectives of the PMS are to observe the frequency, type, and degree of device deficiency to assure the safety of the new medical device (XIENCE PRIME) as well as to collect information on evaluation of the efficacy and safety for reevaluation by Pharmaceuticals and Medical Devices Agency (PMDA).</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Coronary Occlusion</mesh_term>
	<criteria>Patients with ischemic heart disease who are eligible for treatment with XIENCE PRIME Everolimus Eluting Stent Patient provides Informed Consent Form If it is known at the time of index procedure that the patient is not able to return for the 8month followup visit for angiogram and for the 1year clinical followup, then the patient should not be registered in the PMS.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Angioplasty</keyword>
	<keyword>Drug eluting stents</keyword>
	<keyword>Stents</keyword>
	<keyword>Real world</keyword>
</DOC>